OnKure Therapeutics Inc. (OKUR)

3.06

0.02 (0.66%)

At close: Apr 15, 2025, 3:59 PM

3.12

1.97%

After-hours: Apr 15, 2025, 05:41 PM EDT

Company Description

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.

The company focuses on developing selective inhibitors of histone deacetylases.

Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.

The company was incorporated in 2011 and is based in Boulder, Colorado.

OnKure Therapeutics Inc.

Address: 6707 Winchester Circle Boulder, Colorado United States
Website	https://onkuretherapeutics.com

Name	Position
Dr. Nicholas A. Saccomano Ph.D.	President, Chief Executive Officer & Director
Jason A. Leverone CPA	Chief Financial Officer
Dr. Duncan Walker Ph.D.	Chief Development Officer
Dr. Dylan Hartley Ph.D.	Chief Scientific Officer
Dr. James Blake Ph.D.	Senior Vice President of Computational Drug Discovery
Dr. Kevin S. Litwiler Ph.D.	Senior Vice President of DMPK & Clinical Pharmacology
Dr. Mark L. Boys Ph.D.	Senior Vice President of Discovery Chemistry
Dr. Samuel Agresta M.D., M.P.H.	Chief Medical Officer
Roberta Alton	Senior Vice President of Clinical Operations
Rogan P. Nunn J.D.	General Counsel & Secretary